🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TODAY: BioAge CEO Kristen Fortney joins a Clubhouse Q&A about the @beOnDeck Longevity Biotech Fellowship. ODLB brings people together to build, join, and invest in revolutionary longevity biotechnology startups! Monday, July 12, 10:30 AM PDT clubhouse.com/event/Mwab7e2B

Be sure to check out the latest Prime Movers Lab webinar on Wednesday at 12:00 PT/3:00 ET exploring the technologies that are helping us live longer and the startups making the biggest breakthroughs. Register here: bit.ly/3e4XmWy

great article on Rubedo Life Sciences by Longevity Technology longevity.technology/longevity-seno…

The RIse of Longevity Therapeutics - nice article on Pharma Exec by Dr. @Marco4Quarta12 CEO & CoFounder of Rubedo pharmexec.com/view/the-rise-…

longevity.technology/news/rubedo-an…

Phaedon Institute is hosting a Senotherapeutics Summit at Buck on Nov 7-8. Fantastic line up of speakers and panelists all focused on #senescence. Register here: phaedon.institute/summit/registe… #phaedoninstitute #senotherapeuticsummit2023 #longevity

"There are no competitors in senotherapeutics – we are all collaborators." Great article by Longevity Technology discussing the upcoming #SenoTherapeuticsSummit with our President Marco Quarta, PhD!

We are excited to share the report of the Seno-Therapeutics Summit 2023. You can read the paper now published on Nature Portfolio journal npj #aging by Summit chairs Dr. Marco Quarta, our President, and Dr. Marco Demaria, our Chairman of the SAB. nature.com/articles/s4151…

Rubedo lands $40m to advance senescence-targeting therapeutics into clinical trials... Longevity biotech Rubedo Life Sciences plans Phase 1 #senotherapeutics trial this year as it seeks to keep people ‘biologically young.’ #longevity #investment #senescence longevity.technology/news/rubedo-la…

💣New investment for IAG #businessangels: Rubedo Life Sciences 👩‍🔬 #biopharmaceuticals Rubedo Life Sciences secures a substantial $40M Series A financing round, with a focus on advancing groundbreaking therapies targeting age-related diseases. italianangels.net/en/news/new-in…

.Rubedo Life Sciences just brought in $40 million in a series A financing round co-led by Khosla Ventures and Ahren Innovation Capital. The start-up will develop medicines for aging cells that drive skin and fibrotic diseases: cen.acs.org/business/start…

Celebrating with Khosla Ventures team and Rubedo team our Series A and the partnering deal with Beiersdorf AG

We are stocked to announced that we closed our $40M+ Series A led by Khosla Ventures and Ahren Innovation capital to advance the company to the clinic with our first program, entry point to broader therapeutic areas of chronic diseases of aging businesswire.com/news/home/2024…

We are excited to announced a strategic partnership with Beiersdorf AG to advance the skincare industry with a disruptive and innovative product, born from deep science of aging and cellular senescence biology businesswire.com/news/home/2024…

Sharing the latest from Nature Neuroscience journal: Our computational work at Rubedo Life Sciences in collaboration with leading scientists from Stanford Medicine is featured on the cover. Grateful for the opportunity to contribute to such impactful work in a small capacity. nature.com/articles/s4159…

breakthrough discovery: featured on the cover, our new paper on Nature Neuroscience with Prof. Tawfik lab at Stanford University, showing first-in-class senescence sensory neurons to treat neuropathic pain businesswire.com/news/home/2025…

We’re excited to announce a major milestone at Rubedo Life Sciences: our first patients have been dosed! With this, Rubedo officially enters the clinic as a clinical-stage longevity biotech. businesswire.com/news/home/2025…